RNAC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 57.90%

Insider Buying (Last 12 Months): $2,010,993.42

Insider Selling (Last 12 Months): $2,416,892.05

Cartesian Therapeutics Insider Trading History Chart

Cartesian Therapeutics Share Price & Price History

^$10.67

▲ +0.31 (2.99%)

As of 04/11/2025 05:00 PM ET

Days: 30 | 90 | 365

Cartesian Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2025	Blaine Davis	CFO	Sell	4,028	$16.83	$67,791.24	94,811
1/6/2025	Metin Kurtoglu	CTO	Sell	2,458	$16.83	$41,368.14	62,258
1/6/2025	Milos Miljkovic	Insider	Sell	948	$16.83	$15,954.84	35,393
1/3/2025	Blaine Davis	CFO	Sell	3,961	$16.72	$66,227.92	98,839
1/3/2025	Metin Kurtoglu	CTO	Sell	2,417	$16.72	$40,412.24	64,716
1/3/2025	Milos Miljkovic	Insider	Sell	932	$16.72	$15,583.04	36,341
11/21/2024	Metin Kurtoglu	CTO	Sell	32,789	$16.67	$546,592.63	51,033
11/18/2024	Metin Kurtoglu	CTO	Sell	34,400	$18.39	$632,616.00	51,033
11/14/2024	Metin Kurtoglu	CTO	Sell	25,900	$16.44	$425,796.00	51,033
11/14/2024	Milos Miljkovic	Insider	Sell	35,000	$16.13	$564,550.00	18,273
10/4/2024	Timothy A Springer	Director	Buy	80,301	$22.58	$1,813,196.58	8,023,766
10/2/2024	Timothy A Springer	Director	Buy	5,514	$17.38	$95,833.32	7,823,559
8/12/2024	Timothy A Springer	Director	Buy	8,016	$12.72	$101,963.52	11,509
3/18/2024	Timothy A Springer	Director	Buy	634	$18.00	$11,412.00	1,035,780
3/14/2024	Timothy A Springer	Director	Buy	21,612	$16.20	$350,114.40	1,017,228
3/11/2024	Timothy A Springer	Director	Buy	40	$19.50	$780.00	3,213
3/8/2024	Timothy A Springer	Director	Buy	160	$19.80	$3,168.00	3,173
2/6/2024	Timothy A Springer	Director	Buy	26	$19.50	$507.00	2,933
1/17/2024	Timothy A Springer	Director	Buy	26	$20.70	$538.20	2,907

See Full Table

SEC Filings (Institutional Ownership Changes) for Cartesian Therapeutics (NASDAQ:RNAC)

86.95% of Cartesian Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cartesian Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/8/2025	Rhumbline Advisers	13,006	$0.17M	0.0%	+27.5%	0.050%
2/17/2025	Two Sigma Investments LP	11,812	$0.21M	0.0%	-8.5%	0.046%
2/17/2025	MPM Bioimpact LLC	721,139	$12.92M	1.8%	+14.6%	2.837%
2/17/2025	Nuveen Asset Management LLC	72,099	$1.29M	0.0%	+197.8%	0.284%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	5,786	$0.10M	0.0%	+44.8%	0.023%
2/17/2025	Citadel Advisors LLC	315,000	$5.64M	0.0%	-16.2%	1.239%
2/17/2025	Bank of America Corp DE	11,690	$0.21M	0.0%	+54.4%	0.046%
2/17/2025	683 Capital Management LLC	125,000	$2.24M	0.1%	+65.7%	0.492%
2/14/2025	Northern Trust Corp	95,030	$1.70M	0.0%	+50.6%	0.374%
2/14/2025	Virtus ETF Advisers LLC	3,533	$63K	0.0%	N/A	0.014%
2/14/2025	MetLife Investment Management LLC	6,667	$0.12M	0.0%	N/A	0.026%
2/13/2025	Barclays PLC	19,099	$0.34M	0.0%	+64.5%	0.075%
2/13/2025	Renaissance Technologies LLC	13,800	$0.25M	0.0%	N/A	0.054%
2/13/2025	Wells Fargo & Company MN	4,847	$87K	0.0%	+112.7%	0.019%
2/12/2025	Geode Capital Management LLC	221,257	$3.96M	0.0%	+63.0%	0.870%
2/12/2025	JPMorgan Chase & Co.	274,740	$4.92M	0.0%	-11.1%	1.081%
2/11/2025	Corebridge Financial Inc.	5,122	$92K	0.0%	+32.6%	0.020%
2/10/2025	Erste Asset Management GmbH	173,566	$3.26M	0.0%	-93.6%	0.683%
2/6/2025	Charles Schwab Investment Management Inc.	26,803	$0.48M	0.0%	+40.7%	0.105%
2/4/2025	Bank of New York Mellon Corp	19,407	$0.35M	0.0%	+28.5%	0.076%
1/31/2025	New York State Common Retirement Fund	3,902	$70K	0.0%	-23.5%	0.015%
1/30/2025	Rhumbline Advisers	10,201	$0.18M	0.0%	+10.0%	0.040%
1/27/2025	Mirae Asset Global Investments Co. Ltd.	4,562	$82K	0.0%	+22.8%	0.018%
1/24/2025	China Universal Asset Management Co. Ltd.	5,389	$97K	0.0%	N/A	0.021%
12/26/2024	JPMorgan Chase & Co.	309,018	$4.98M	0.0%	+0.9%	1.216%
11/19/2024	Barclays PLC	11,611	$0.19M	0.0%	+208.6%	0.046%
11/16/2024	Geode Capital Management LLC	135,700	$2.19M	0.0%	+2.1%	0.534%
11/15/2024	Barclays PLC	11,611	$0.19M	0.0%	+208.6%	0.046%
11/15/2024	State Street Corp	157,495	$2.54M	0.0%	+2.5%	0.620%
11/15/2024	Ikarian Capital LLC	52,193	$0.84M	0.1%	-78.5%	0.205%
11/13/2024	Great Point Partners LLC	200,000	$3.22M	0.9%	N/A	0.787%
11/13/2024	BNP Paribas Financial Markets	1,651	$27K	0.0%	+122.5%	0.006%
11/13/2024	FMR LLC	2,851,830	$45.97M	0.0%	+458.3%	11.219%
10/23/2024	Lake Street Advisors Group LLC	15,822	$0.26M	0.0%	-50.0%	0.074%
9/16/2024	Point72 DIFC Ltd	1,725	$47K	0.0%	N/A	0.008%
9/16/2024	Cubist Systematic Strategies LLC	13,010	$0.35M	0.0%	N/A	0.061%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	1,824	$49K	0.0%	N/A	0.009%
8/27/2024	Logos Global Management LP	90,000	$2.43M	0.2%	N/A	0.506%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	1,824	$49K	0.0%	N/A	0.009%
8/14/2024	Cubist Systematic Strategies LLC	13,010	$0.35M	0.0%	N/A	0.061%
8/14/2024	Point72 DIFC Ltd	1,725	$47K	0.0%	N/A	0.008%
8/14/2024	Marshall Wace LLP	30,038	$0.81M	0.0%	N/A	0.140%
8/14/2024	Logos Global Management LP	90,000	$2.43M	0.2%	N/A	0.421%
8/9/2024	Renaissance Technologies LLC	17,052	$0.46M	0.0%	-96.9%	0.096%
8/6/2024	Lake Street Advisors Group LLC	31,644	$0.86M	0.0%	N/A	0.178%
8/1/2024	Rhumbline Advisers	8,487	$0.23M	0.0%	-93.5%	0.048%
7/26/2024	Bank of New York Mellon Corp	19,916	$0.54M	0.0%	-93.7%	0.112%
7/22/2024	Hall Laurie J Trustee	1,759	$48K	0.0%	-96.7%	0.010%
5/17/2024	Artal Group S.A.	9,136,635	$5.94M	0.2%	N/A	171.098%
5/14/2024	American International Group Inc.	56,202	$37K	0.0%	N/A	1.052%
5/10/2024	Vanguard Group Inc.	6,315,113	$4.11M	0.0%	N/A	118.172%
5/7/2024	SG Americas Securities LLC	47,134	$31K	0.0%	N/A	0.883%
5/3/2024	Delphi Financial Group Inc.	660,852	$0.43M	0.3%	N/A	12.261%
5/1/2024	BNP Paribas Financial Markets	59,125	$38K	0.0%	N/A	1.097%
4/23/2024	Hall Laurie J Trustee	52,775	$34K	0.0%	N/A	0.979%

Data available starting January 2016

See Full Table

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $10.67

$10.30

$11.16

50 Day Range

MA: $16.06

$9.52

$19.67

52 Week Range

Now: $10.67

$8.85

$41.87

Volume

195,506 shs

Average Volume

117,567 shs

Market Capitalization

$276.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Who are the company insiders with the largest holdings of Cartesian Therapeutics?: Cartesian Therapeutics' top insider shareholders include:
Timothy A Springer (Director)
Blaine Davis (CFO)
Metin Kurtoglu (CTO)
Milos Miljkovic (Insider)
Learn More about top insider investors at Cartesian Therapeutics.
Who are the major institutional investors of Cartesian Therapeutics?: Cartesian Therapeutics' top institutional investors include:
Rhumbline Advisers — 0.05%
Learn More about top institutional investors of Cartesian Therapeutics stock.
Which major investors are buying Cartesian Therapeutics stock?: In the last quarter, RNAC stock was purchased by institutional investors including:
Rhumbline Advisers